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Evidence on circulating microRNAs (miRNAs) is indisputably opening a new era in
systemic and tissue-specific biomarker research, highlighting new inter-cellular and
inter-organ communication mechanisms. Circulating miRNAs might be active messengers
eliciting a systemic response as well as non-specific “by-products” of cell activity and even
of cell death; in either case they have the potential to be clinically relevant biomarkers
for a number of physiopathological processes, including inflammatory responses and
inflammation-related conditions. A large amount of evidence indicates that miRNAs can
exert two opposite roles, activating as well as inhibiting inflammatory pathways. The
inhibitory action probably relates to the need for activating anti-inflammatory mechanisms
to counter potent proinflammatory signals, like the nuclear factor kappaB (NF-κB) pathway,
to prevent cell and tissue destruction. MiRNA-based anti-inflammatory mechanisms may
acquire a crucial role during aging, where a chronic, low-level proinflammatory status
is likely sustained by the cell senescence secretome and by progressive activation of
immune cells over time. This process entails age-related changes, especially in extremely
old age, in those circulating miRNAs that are capable of modulating the inflammatory
status (inflamma-miRs). Interestingly, a number of such circulating miRNAs seem to be
promising biomarkers for the major age-related diseases that share a common chronic,
low-level proinflammatory status, such as cardiovascular disease (CVD), type 2 diabetes
mellitus (T2DM), Alzheimer Disease (AD), rheumatoid arthritis (RA), and cancers.
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Inflamma-miRs
The inflammatory response comprises complex biological reac-
tions that require a fine-tuned integration between a range
of immune system cell classes and an extensive network of
biomolecules, which until recently had been thought to be largely
cytokines. However, identification of a vast repertoire of non-
coding microRNA (miRNA) in the mammalian genome has
completely revolutionized our understanding of most biological
processes, including inflammation (Nilsen, 2007). MiRNAs play
a significant role in gene regulation acting as repressors as well as
activators, mainly at the post-transcriptional level (Breving and
Esquela-Kerscher, 2010). Since a single miRNA can target several
genes, and multiple miRNAs share common targets, miRNAs are
particularly suited for regulating processes and pathways at the
“network” level (Inukai and Slack, 2013).
Sensing of dangerous signals by the innate immune sys-
tem involves a number of germline-encoded pattern recognition
receptors (PRRs) that can detect both conserved pathogen-
associated molecular profiles (PAMPs) expressed on micro-
organisms and altered endogenous ligands, mostly released by
necrotic, senescent, and/or damaged cells (DAMPs). Among
PRRs, toll-like receptors (TLRs) play a central role, since their
engagement activates a potent proinflammatory pathway (Kawai
and Akira, 2011). TLR signaling initiates from different adaptor
proteins, such as myeloid differentiation factor 88 (MyD88) or
TIR-domain-containing adapter protein-inducing interferon-β,
which in turn activate several downstream pathways, leading to
activation of transcription factor nuclear factor kappaB (NF-κB),
mitogen-activated protein kinases (MAPKs), and members of the
interferon regulatory factor family (Dunne and O’Neill, 2005).
Fine tuning of TLR signaling prevents generation of harmful
and inappropriate inflammatory responses without lowering the
surveillance for potentially dangerous signals. Deregulation of the
whole network can have destructive effects and lead to tissue dam-
age: this is a hallmark of chronic inflammation, which is often
associated with age-related diseases (Olivieri et al., 2013a).
A mounting body of evidence has been documenting a rel-
atively small number of miRNAs that are involved in regulat-
ing inflammation: their prototypes are miR-155, miR-21, and
miR-146a (Quinn and O’Neill, 2011), hereinafter referred to as
inflamma-miRs.
In physiological conditions transcription of miR-155, miR-
21, and miR-146a is at baseline levels; however, initiation of
proinflammatory TLR signaling immediately results in strong co-
induction of their expression through a mechanism that is largely
NF-κB-dependent (Boldin and Baltimore, 2012).
Although the importance of inflamma-miRs in innate immune
response regulation is widely accepted, the molecular mechanism
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of their action has proved to be highly complex. Early investi-
gations disclosed that miR-146a acts as a negative regulator of
TLR signaling by targeting both tumor necrosis factor receptor-
associated factor 6 (TRAF6) and IL-1 receptor-associated kinase
1 (IRAK-1) (Taganov et al., 2006). MiR-21 was found to down-
regulate the expression of IRAK and MyD88 (Chen et al.,
2013), as well as of programmed cell death protein 4 (PDCD4),
switching the cell program from proinflammatory to anti-
inflammatory, mainly as reflected by IL-10 production (Sheddy
et al., 2010).
Additional findings showing that miR-155 can also nega-
tively modulate TLR signaling by targeting MyD88, Tak1-binding
protein 2 (TAB2) (Ceppi et al., 2009), and the I-κ-B kinase
ε (IKKε), (Liang et al., 2011) have generated a model where
inflamma-miRs operate as a negative feedback loop to protect
the organism against overwhelming inflammation. However, sub-
sequent research has disclosed that inflamma-miRs could play
a dual function, inhibiting as well as inducing TLR signal-
ing (Kondo et al., 2012). This is the case of miR-155, which
both suppresses and enhances TLR signaling by silencing Src
homology 2 domain-containing protein tyrosine phosphatase-
1 (SHP-1), a negative regulator of IRAK activity (O’Connell
et al., 2009); suppressor of cytokine signaling 1 (SOCS1); and
B-cell lymphoma 6 protein (BCL6), a transcription factor that
attenuates NF-κB signaling (Nazari-Jahantigh et al., 2012). A
similar action is also exerted by miR-21, which can function
as an agonist of single-stranded RNA-binding TLRs and can
therefore induce NF-κB activation and secretion of inflammatory
molecules (Fabbri et al., 2012).
Although inflamma-miRs are co-induced during TLR signal-
ing, several observations suggest that they do not act redundantly
and simultaneously, but rather cooperate to control TLR sig-
naling through functionally different performances. At least for
miR-146a and miR-155 this has recently been confirmed by
Schulte and colleagues, who found different induction behav-
iors and mRNA target profiles in the response to microbial
lipopolysaccaride (LPS), (Schulte et al., 2013). Such coordination
of inflamma-miRs could go beyond suppression of TLR signal-
ing and contribute to regulating the immunity/inflammation
balance, as proposed by Akira’s group (Kondo et al., 2012).
Knockout mouse models have been instrumental in shed-
ding light on the role of inflamma-miRs in inflammation
and inflammation-related diseases. Transcriptome analysis of
bic/miR-155-deficient CD4+ T cells in mice identified a wide
spectrum of miR-155-regulated genes, including cytokines,
chemokines, and transcription factors, suggesting that bic/miR-
155 plays a key role in immune system homeostasis and function
(Rodriguez et al., 2007). Knockout of miR-146a gene in C57BL/6
mice involves increased transcription of NF-κB-regulated genes
(Zhao et al., 2011). These animals also develop myeloid sar-
comas and lymphomas as well as chronic myeloproliferation
in bone marrow. Genetic ablation of NF-κB p50 suppresses
the myeloproliferation, demonstrating that NF-κB dysregulation
is responsible for the myeloproliferative disease (Zhao et al.,
2011).
Details on the role of inflamma-miRs in controlling TLR
signaling are just beginning to be explored, and further
investigations are warranted to gain insights not only into their
individual contribution to the homeostasis of the innate immune
response, but also into the consequences of their deregulation in
conditions characterized by chronic inflammation.
The most recent evidence for the involvement of inflamma-
miRs in modulating the proinflammatory response at the cell level
is summarized in Table 1. Few cellular inflamma-miRs have been
reported to be modulated in plasma/serum samples in different
physiopathological conditions, as depicted in Table 2.
RELATIONSHIP BETWEEN TISSUE AND CIRCULATING
Inflamma-miRs
It is becoming increasingly clear that multiple miRNAs can be
deregulated in several diseases (Reid et al., 2011). Detection and
identification of stable miRNAs in body fluids has opened a new
era in systemic biomarker research directed at improving clinical
diagnosis/prognosis within translational medicine. The numer-
ous reports of changes in miRNA expression have often failed to
clarify whether they are the cause or the effect of malfunction.
Identification of multiple miRNA changes in plasma is impor-
tant, because specific miRNA combinations unique to a normal
physiological or pathological state can provide a useful reference.
These findings also raise several questions: do circulating miRNA
levels match tissue expression levels? If this is the case, does it
also apply to pathological conditions? A greater understanding
of the relationship between the level of tissue and plasma miR-
NAs should help uncover the origin and/or function of circulating
miRNAs.
So far only a limited number of studies, mostly in oncology,
have addressed the issue. Findings have been controversial: some
researchers described a similar trend of alteration both in cir-
culating and tissue miRNAs (Brase et al., 2011), whereas others
reported that only a subset of circulating miRNAs reflect tissue
cellular abundance (e.g., mammary epithelial tumor), and sug-
gested that cells might have developed a mechanism that selects
specific miRNAs for release or retention (Pigati et al., 2010).
Studies of animal models found distinct roles for circulating and
tissue miRNAs (Waters et al., 2012).
The way circulating miRNAs are delivered into the
bloodstream is also poorly understood. Evidence from sev-
eral studies indicates that miRNAs exist freely in the systemic
circulation despite their susceptibility to degradation by extra-
cellular RNAses, raising the issue of which mechanisms underpin
their unexpected stability. On the one hand, different studies have
revealed that miRNAs are secreted into the extracellular space or
the bloodstream either in microvesicles or in exosomes (Valadi
et al., 2007; Collino et al., 2010; Hosoda et al., 2011). Secretory
exosomes are promising candidates for intercellular miRNAs
transfer not only because they provide a protected environment,
but also because they may directly transfer internal components
to target cells by receptor-mediated interactions. This is con-
sistent with the observation that plasma exosomes can deliver
exogenous short interfering RNA to monocytes and lymphocytes
(Wahlgren et al., 2012). On the other hand, a number of reports
have shown that a significant fraction of extracellular miRNAs
reside outside vesicles and act in an exosome-independent man-
ner, protected by RNA-binding proteins such as nucleophosmin
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Table 1 | Cellular inflamma-miRs.
MiRs Cell types mRNA targets Signaling References
MiR-9 Polymorphonuclear
neutrophils and monocytes
NFKB1 TLRs Bazzoni et al., 2009
MiR-21 Monocytes
Myofibroblasts
HUVEC
Immune cells
Hepatocytes
Hepatocytes
TLRs
PDCD4
PPARα
TLR-8
MyD88
IRAK1
TLRs
TLRs
TLRs
TLRs
TLRs
Crone et al., 2012
Yao et al., 2011
Zhou et al., 2011
Fabbri et al., 2012
Chen et al., 2013
Chen et al., 2013
MiR-29a Immune cells TLR-8 TLRs Fabbri et al., 2012
MiR-125a
MiR-125b
Diffuse large B-cell lymphoma TNFAIP3 TLRs Kim et al., 2012
MiR-126 Endothelial cells VCAM-1 Vascular inflammation Harris et al., 2008
MiR-146a Intestinal epithelial cells
Astrocytes
HUVECs
HUVECs
Myofibroblasts
IRAK-1
IRAK-1
IRAK-1
IRAK-1
SMAD4
TLRs
TLRsTLRs
TLRs
TGF-β1
Chassin et al., 2012
Chassin et al., 2012
Iyer et al., 2012
Olivieri et al., 2012a,b
Liu et al., 2012
MiR-155 MSCs
Macrophages
Macrophages
TAB2
BCL6
SOCS1
iNOS
TLRs
TLRs
Xu et al., 2013
Nazari-Jahantigh et al., 2012
Sun et al., 2012
MiR-195 Hepatocellular carcinoma IKKα, TAB3 TLRs Ding et al., 2013
MiR-199a Endometrial stromal cells IKKβ TLRs Dai et al., 2012
MiR-517a/c Cell lines TNIP1 TLRs Olarerin-George et al., 2013
Let-7
Let-7i
Primary cultured T cells
Human biliary epithelial cells
TLR-4 IL-13 secretion,
TLRs
Kumar et al., 2011
Chen et al., 2007
BCL6, B-cell lymphoma 6 protein; HUVECs, human umbilical vein endothelial cells; IKKα and IKKβ, inhibitor of kappa B (IκB) kinase α and β; iNOS, nitric oxide
synthase; IRAK-1, interleukin-1 receptor-associated kinase 1; MSCs, Mesenchymal Stem Cell; NFκB1, nuclear factor κB1; PDCD4, programmed cell death 4;
MyD88, myeloid differentiation factor 88; PPARα, peroxisome proliferator-activated receptor-α; SMAD4, SMAD family member 4; SOCS1, suppressor of cytokine
signaling 1; TAB2, transforming growth factor-β-activated kinase 1 (TAK1)-binding protein 2; TAB3, TAK1-binding protein 3; TLRs, toll-like receptors; TNFAIP3, tumor
necrosis factor, alpha-induced protein 3; TNIP1, TNFAIP3 interacting protein 1; VCAM-1, vascular cell adhesion molecule 1.
1 (NPM1) (Wang et al., 2010) or argonaute protein 2 (Ago2),
(Turchinovich et al., 2011). Whether circulating miRNAs are
found in soluble free form or are predominantly transported via
secreted microvesicles/exosomes is still unclear, since evidence
has been found for both mechanisms. However, it has recently
been reported that the form of delivery of circulating miRNAs
could depend on the type of tissue injury, suggesting a different
role for each mode of systemic transport. Bala and co-workers
documented this mechanism for circulating inflamma-miRs
using different liver disease mouse models: in inflammatory
liver injury and alcoholic liver disease (ALD) serum/plasma
miR-122 and miR-155 were predominantly associated with
the exosome-rich fraction, whereas in drug (acetaminophen,
APAP)-induced liver injury (DILI/APAP) the same miRNAs
were found mainly in protein-rich, soluble free form (Bala et al.,
2012).
Evidence has also been found that blood cells are the major
contributors to circulating miRNAs (Pritchard et al., 2012),
However, analysis of inflamma-miRs from patients with acute
coronary syndrome (ACS) documented that their levels in plasma
and peripheral blood mononuclear cells (PBMCs) did not corre-
late in all subjects (Yao et al., 2011). This suggests that other cells
may contribute to circulating inflamma-miRs. Endothelial cells
could exert such a role, especially during normal aging and in age
related-diseases. Indeed human endothelial cells and circulating
progenitor endothelial cells can acquire the senescence-associated
secretory phenotype (SASP) during replicative senescence in vitro
(Olivieri et al., 2012b, 2013c). The accumulation of endothelial
senescent cells in vivo, and stimulation of immune cells over time,
could strongly contribute to promoting and maintaining low-
level chronic systemic inflammation (Orjalo et al., 2009; Davalos
et al., 2010; Campisi et al., 2011).
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Table 2 | Circulating inflamma-miRs in age-related diseases.
Circulating
miRs
Disease Sample(s) References
MiR-9 AD Cerebrospinal
fluid
Alexandrov et al., 2012
MiR-21 AMI, CVD
AD
Breast cancer
Plasma
Cerebrospinal
fluid
Serum
Olivieri et al., 2012a,b
Alexandrov et al., 2012
Mar-Aguilar et al., 2013
MiR-29a Colorectal liver
metastasis
Serum Wang et al., 2012
MiR-126 T2DM
Malignant
mesothelioma
Plasma
Plasma
Zampetaki et al., 2010
Tomasetti et al., 2012
MiR-146 T2DM
AMI, CVD
AD
Plasma
Plasma
Cerebrospinal
fluid
Balasubramanyam
et al., 2011
Olivieri et al., 2012a,b
Alexandrov et al., 2012
MiR-155 AMI
Atherosclerosis
Breast cancer
Plasma
Plasma
Serum
Matsumoto et al., 2012
Wei et al., 2013
Mar-Aguilar et al., 2013
Liu et al., 2013
AD, Alzheimer Disease; AMI, acute myocardial infarction; CVD, cardiovascular
disease; T2DM, type 2 diabetes mellitus.
CIRCULATING Inflamma-miRs IN AGING
A progressive increase in circulating acute-phase proteins
and proinflammatory mediators, i.e., proteases, cytokines,
chemokines, and growth factors, has been described as a gen-
eral feature of the aging process and has been denominated
inflamm-aging (Franceschi et al., 2000). Age-associated chronic
inflammation has mainly been attributed to progressive activa-
tion of immune cells over time and to accumulation of senescent
cells with a proinflammatory secretory phenotype (Olivieri et al.,
2013b). The complex inflamma-ging phenotype is the result of
age-related cell/tissue adaptation and remodeling interacting with
genetic/epigenetic factors.
Even though TLR family members do not show consistent
age-dependent changes across model systems, there is evidence
for impaired downstream signaling events during aging, includ-
ing inhibition of positive effectors and activation of negative
modulators of TLR signaling (Olivieri et al., 2013a). Therefore,
during aging inflamma-miR levels progressively increase in order
to stem the cell and tissue damage induced by the low-level
chronic inflammation, also likely sustained by the cell senescence
secretome (Murray and Smale, 2012).
We have recently described an increased expression of miR-
146a in human umbilical vein endothelial cells (HUVECs) and
in aortic and coronary endothelial cells (respectively HAECs
and HCAECs) during replicative senescence, thus demonstrat-
ing that TLR/NF-κB activation and cell senescence can be
modulated by the samemiRNAs (Olivieri et al., 2012b). MiR-146a
is highly expressed also in aged mice (Jiang et al., 2012).
In addition, lack of response by aged mouse macrophages
to stimulation with LPS and proinflammatory cytokines indi-
cates interruption of the negative feedback loop of miR-
146a (Jiang et al., 2012). Altogether, these data lend support
to the hypothesis that cellular senescence and TLR signaling
activation may be closely interconnected and share common
regulators.
Given the involvement of miRNAs in gene expression regula-
tion, a peculiar modulation of their expression might contribute
to efficient homeostasis in human aging. It is worth stressing
that exceptionally long survival requires dynamic preservation of
optimal levels of physiological variables, and that the mean lev-
els of many biomarkers of aging are not stable, but change in
the course of life (Spazzafumo et al., 2013). Only four studies
have compared the miRNA expression profile of centenarians and
younger subjects. They have shown a significant overlap between
the miRNA profiles of centenarians and young individuals and a
different profile in octogenarians, supporting the hypothesis that
achievement of extreme longevity probably requires a special gene
expression regulation (ElSharawy et al., 2012; Gombar et al., 2012;
Olivieri et al., 2012a; Serna et al., 2012). Interestingly, all these
studies showed miR-21 deregulation in centenarians compared
with younger subjects. Age-related changes in the expression of
miR-21 and miR-21∗ have recently been reported also in mouse
heart, the major changes occurring from middle to old age
(Zhang et al., 2012).
Modulation of miR-21 expression in plasma, circulating cells,
and tissues of very old subjects and animals is not surpris-
ing to those who believe that miR-21 lies at the intersection of
senescence, inflammation, and age-related diseases. Our group
showed a positive correlations between circulating miR-21 and
two important biomarkers of inflammation: C-reactive protein
(CRP) and fibrinogen (Olivieri et al., 2012a,b). These data sug-
gest that centenarians may have a better balance of their systemic
inflammatory status compared with elderly subjects. Notably, we
also found age-related changes in circulating miR-146a levels that
were quite similar to those described for miR-21 (Olivieri et al.,
2012a,b, our unpublished data). Interestingly, analysis of global
miRNA expression in the peripheral blood of adult women has
shown that miR-155 is one of the most up-regulated miRNAs
among older women (Sredni et al., 2011).
CIRCULATING Inflamma-miRs IN AGE-RELATED DISEASES
Abundant data continue to support the hypothesis that pro-
gressive up-regulation of inflammatory gene expression and
high levels of inflammatory signaling facilitate the develop-
ment and progression of the major age-related diseases, such
as cardiovascular disease (CVD), type 2 diabetes mellitus
(T2DM), Alzheimer Disease (AD), rheumatoid arthritis (RA),
and cancers. Patients suffering from such diseases show sub-
clinical/clinical inflammation and, interestingly, deregulation of
most circulating inflamma-miRs (Wang et al., 2012). Since mul-
tiple co-expressed miRNAs can cooperatively regulate a given
biological process by targeting common components of that pro-
cess, the development and progression of human diseases could
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be associated with abnormal regulation of multiple miRNAs
functioning cooperatively. Some of the most recent data show-
ing that cellular and circulating inflamma-miR deregulation is
shared by the major human age-related diseases are summarized
below.
Inflamma-miRs AND T2DM
Recently, some of the miRNAs that we have designated inflamma-
miRs, including miR-21 and miR-146a, were identified as novel
players in β-cell failure elicited by proinflammatory cytokines
in both in vitro and in vivo animal models (Roggli et al.,
2010). Reduced miR-146a levels were also reported in PBMCs
from Asian Indian patients with T2DM, in association with
insulin resistance, poor glycaemia control, specific proinflam-
matory cytokine gene variants, and high levels of plasma TNFα
and IL-6 (Balasubramanyam et al., 2011). Importantly, glucose
concentrations were also reported to correlate negatively with
circulating miR-126 in endothelial apoptotic bodies (Zampetaki
et al., 2010); similarly, in patients with diabetes the reduction in
miR-126 was seen to be confined to circulating vesicles in plasma
(Zampetaki et al., 2010). Interestingly, miR-126 can modulate
endothelial cell activation in response to systemic inflammatory
stimuli, and can down-regulate the expression of IKBα, an impor-
tant inhibitor of NF-κB signaling (Asgeirsdóttir et al., 2012; Feng
et al., 2012).
Inflamma-miRs AND CVD
In patients with CVD activation of innate immunity leads
to an acute inflammatory reaction. There is evidence that
inflamma-miR may contribute to the development/restraint of
this inflammatory response: circulating inflamma-miRs could
thus be clinically relevant diagnostic/prognostic biomarkers in
CVD patients. MiR-21 plays important roles in cardiovascu-
lar and pulmonary disorders, including cardiac and pulmonary
fibrosis and myocardial infarction, and also regulates vari-
ous immunological and developmental processes (Kumarswamy
et al., 2011).
We recently reported significantly higher circulating miR-21
and miR-146a levels in elderly patients with acute myocardial
infarction (AMI) and/or heart failure compared with healthy sub-
jects (Olivieri et al., 2012c). Circulating miR-155 were higher in
those post-AMI patients who experienced cardiac death within
1 year (Matsumoto et al., 2012). Elevated miR-155 levels are
also found in proinflammatory macrophages and atherosclerotic
lesions, even though the effects of miR-155 seem to be different in
early vs. advanced atherosclerosis (Wei et al., 2013). Recent stud-
ies suggest that miRNA deregulation may limit cardiovascular
repair responses and result in an altered function and differentia-
tion of cardiovascular progenitor cells and endothelial progenitor
cells (EPCs), modulating endothelial regeneration and cardiomy-
ocyte homeostasis and playing a crucial role in CVD (Jakob
and Landmesser, 2012). Aging-associated senescence results in
reduced EPC number and function, contributing to enhanced
cardiac risk, reduced angiogenic capacity, and impaired cardiac
repair effectiveness. Mounting evidence supports a role for miR-
NAs in vascular homeostasis, and miR-21 was found to regulate
EPC senescence (Zhu et al., 2013).
Overall, circulating miR-146a, miR-155, and miR-21 are up-
regulated in plasma of CVD patients.
Inflamma-miRs AND AD
Increasing evidence supports a major role for TLRs in brain
injury and their involvement in neurodegenerative disorders
including AD. Components of this inflammatory pathway are
known to contribute to AD, in part through overexpression of
IL-1α and promotion of 42-amino acid amyloid β 42 (Aβ42) pep-
tide generation; in turn IL-1α and amyloid β induce transcription
of the proinflammatory prostaglandin synthase cyclooxygenase-2
(COX-2) gene and stimulate apoptotic brain cell death and neu-
ral tissue degeneration (Mrak and Griffin, 2001). Consistent with
these findings many inflamma-miRs, including miR-9, miR-146a,
andmiR-155, are strongly expressed in human cerebrospinal fluid
(CSF)- and brain tissue-derived extracellular fluid (ECF) from
AD patients and are significantly up-regulated compared with
age-matched controls, suggesting that they may be involved in
modulation or promotion of miRNA-triggered pathogenic sig-
naling throughout the brain and the CNS (Alexandrov et al.,
2012). In AD patients miR-125b, miR-146a, and miR-155 have
been shown to down-regulate complement Factor H (CFH),
an important repressor of innate immunity acting on the cere-
bral inflammation response (Lukiw and Alexandrov, 2012; Lukiw
et al., 2012a).
MiR-146a is among the more extensively investigated miR-
NAs in AD: it is up-regulated in response to IL-1, Aβ42 and
oxidative stress in cultured human neuronal glial cells (Lukiw
et al., 2008; Cui et al., 2010; Holohan et al., 2012; Lukiw and
Alexandrov, 2012). In line with these data it is over-expressed
in temporal cortices and in Aβ42-stressed human astroglial cells,
where it down-regulates IRAK1 while inducing compensatory
up-regulation of IRAK2 (Cui et al., 2010).
Interestingly, miR-146a and miR-155 were detected in the
secretion of stressed human primary neural cells, and the con-
ditioned medium containing miR-146a and miR-155 was found
to induce Alzheimer-type gene expression changes in con-
trol brain cells (Lukiw et al., 2012b). These data suggest that
paracrine transfer of genetic information between cells—either
within the local brain environment or in the cerebrospinal
or systemic circulation—may be the source of both beneficial
and detrimental signals that further modulate the amyloido-
genic, inflammatory, or neurotrophic aspects of the AD process
(Lukiw, 2012).
Further confirmation that inflammatory pathways can con-
tribute to AD development comes from the recent identification
of a role for triggering receptor expressed on myeloid cells 2
(TREM2) in modulating the risk of AD onset (Guerreiro et al.,
2013; Jonsson et al., 2013). TREM2 is an innate immune receptor
expressed on the cell surface of microglia, macrophages, imma-
ture dendritic cells, and white matter in the hippocampus and
neocortex, two areas that partially overlap with those affected
by AD (Jiang et al., 2013). It controls two signaling pathways,
one enhancing phagocytosis and another suppressing inflamma-
tory reactivity. Reduced TREM2 expression is associated with an
increase in microgliosis and neurodegeneration, suggesting that it
modulates AD by enhancing inflammation (Jiang et al., 2013).
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Although the analysis of miRNAs in AD is a relatively new
research area, the data reported so far strongly indicate that
inflamma-miRs could play a key role also in this condition.
Inflamma-miRs AND RA
Altered miRNA expression has been demonstrated in the
inflamed joints of RA patients (Blüml et al., 2011). Interestingly,
miR-155 up-regulation has been documented in synovial mem-
brane and synovial fluid (SF) macrophages from RA patients
in association with reduced expression of its target, SHIP-1,
an inhibitor of inflammation (Kurowska-Stolarska et al., 2011).
Moreover miR-155(−/−) mice show significantly reduced local
bone destruction, attributed to reduced osteoclast generation,
although the severity of the joint inflammation is similar to the
one seen in wild-type mice. These data demonstrate that miR-155
is critically involved in the adaptive and innate immune reactions
leading to autoimmune arthritis (Blüml et al., 2011). In addition
up-regulation of miR-146a, detected in PBMCs from RA patients,
suggests that this miRNA could be a useful marker of disease
activity (Abou-Zeid et al., 2011; Xie et al., 2013). Interestingly, cir-
culatingmiR-21 is increased in the blood of patients with systemic
lupus erythematosus (SLE) or RA, whereas circulating miR-146a
and miR-155 show a trend toward significantly reduced levels
only in SLE (Carlsen et al., 2013).
Inflamma-miRs AND CANCERS
MiRNAs are increasingly being recognized as oncogenes or onco-
suppressors, since they contribute to cell transformation. Solid
tumors are infiltrated by different stromal cells, e.g., fibroblasts,
endothelial cells, lymphocytes and macrophages, that strongly
influence neoplastic processes through a continuous heterotypic
cross-talk (Squadrito et al., 2013). It is therefore not surprising
that inflamma-miRs have been recognized as modulators of can-
cer development and progression (Williams et al., 2008). The
contribution of miR-146a deregulation has been widely docu-
mented (Hurst et al., 2009; Li et al., 2010; Labbaye and Testa,
2012). However, its mechanism of action remains elusive, since
both raised and decreased levels have been described depending
on the type of cancer (Williams et al., 2008). Since miR-146a acts
as a negative feedback loop of inflammation, dynamic changes in
its expression can be expected in cancer tissues depending on the
context of the heterotypic cross-talk.
Interestingly, mice with miR-146a deletion spontaneously
develop subcutaneous flank tumors (Zhao et al., 2011). MiR-
146a has been reported to suppress metastatic activity (Hou
et al., 2012; Hwang et al., 2012), in particular its up-regulation
inhibits cancer cell invasion and metastasis in vitro and in vivo
(Hou et al., 2012). Altogether these findings show that by
counteracting the inflammatory state associated with cell senes-
cence, miR-146a can exert a general tumor suppressing action
by inhibiting cancer development and cancer cell invasion and
metastasis.
MiR-21 is frequently up-regulated in cancer and is implicated
in practically every stage of the cancer process: promotion of cell
proliferation, invasion, and metastasis; genome instability and
mutation; inflammation; replicative immortalization;abnormal
metabolism; angiogenesis; evasion of apoptosis; immune
destruction and growth suppression. This suggests that miR-21
is an oncogene with a key role in resisting programmed cell
death in cancer cells (Buscaglia and Li, 2011). MiR-155 is also
an established “oncomiR” in breast cancer and regulates several
pro-oncogenic pathways including angiogenesis (Czyzyk-Krzeska
and Zhang, 2013).
CONCLUSION
Recent data on inflammation-related miRNAs in normal and
pathological aging outline a complex scenario characterized by
an altered expression of specific miRNAs that we have named
inflamma-miRs, which mainly target the TLRs/NF-κB pathway.
Up-regulation of inflammation markers is a general feature of
the aging process and has been named inflamm-aging. The
inflamm-aging phenotype results from age-related cell and tissue
adaptation/remodeling interacting with the genetic/epigenetic
background. It is a complex phenotype involving not only innate
but also adaptive immunity and affecting a range of tissues and
organs such as gut, fat, liver, muscle and brain. Importantly,
inflamm-aging appears to be accelerated in a variety of age-
associated diseases. Tissue and circulating inflamma-miRs could
contribute to restrain the activity of the senescent cell secretome
and to check the destruction induced by activation of the inflam-
matory response (Murray and Smale, 2012; Olivieri et al., 2013a).
Inflamma-miRshave been implicated in regulation of the immune
and inflammatory response, and their abnormal expression may
contribute to the low-level chronic inflammation that has been
documented both in normal aging and in the major age-related
diseases. Circulating inflamma-miRs could thus have diagnos-
tic/prognostic relevance in human diseases, e.g., CVD, T2DM,
AD, RA, and cancer, which share a common inflammatory back-
ground. Recent data show up-regulation of inflamma-miRs in the
circulation of healthy elderly and old individuals: the increase
is less pronounced in centenarians and greater in patients with
CVD, AD, or cancer. Notably, T2DM patients show decreased
levels of circulating inflamma-miRs, but these data need to be
confirmed in patients with diabetic complications. It is conceiv-
able that the main sources of circulating inflamma-miRs in aging
and age-related diseases are immunity circulating/tissue cells
and endothelial circulating/resident cells. Cell senescence and
inflammatory stimulation can contribute to induce and perpet-
uate systemic inflammation over time, inducing up-regulation of
inflamma-miRs to stem the excessive activation of inflammatory
pathways.
Since this field of research is new and growing, it would not
be surprising if in the near future novel miRNAs were recog-
nized as fine tuners of inflammation and thus added to the list
of inflamma-miRs.
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